HK-listed WuXi Biologics falls as shareholder plans $1.3 bln stake sale

** Shares of WuXi Biologics (Cayman) Inc fall 4.4% to HK$131.90, on course for their worst day since July 8, after a shareholder plans sale of HK$10.32 bln ($1.33 bln) shares at a discount

** Stock biggest percentage decliner in the benchmark Hang Seng Index and the most actively traded by turnover

** Shares sink to their lowest since July 13, and on course to fall for a third consecutive session

** Jiangsu-based company says shareholder WuXi Biologics Holdings Ltd has entered into a block trade agreement with Morgan Stanley & Co International Plc to sell 80 mln shares, or 1.89% stake, to independent third parties at HK$129 apiece

** DEal reduces WuXi Biologics Holdings' stake in the company to 15.34% from about 17.22%

** Both the Hong Kong Hang Seng Commerce & Industry Index and the healthcare index slip 0.2%

** The Hang Seng China Enterprises Index  climbs 0.5%, and the benchmark index gains 0.3%

** As of last close, stock up 34.2% this year